Tokens.com Corp.

The company did not state consolidated revenue, EPS, or gross margin on the call. Management said year-over-year revenue is lower because last year included catch-up revenue from an old backlog, and because the crypto staking business was exited. For the new Realbotix line, management said the tabletop robot will be $12,000 and the full-size robot will be about $55,000, with a $250 deposit to reserve a unit; the configuration app will carry a subscription fee, and the vision system will be an optional paid upgrade. Onco-related work is still in progress: the S-4 is expected this month, the transaction was described as carrying a $125 million valuation for Realbotix LLC, and management said the deal is still on a timeline to close around the end of October/November, subject to SEC review.

Andrew Kiguel’s message was that the company is moving from proof-of-concept into commercialization. He repeatedly emphasized that Realbotix LLC has spent the last two years deploying robots, building an engineering base, and proving use cases in schools, retirement homes, hospitality, and media. His tone was bullish and defiant, especially on competition and press coverage: he said a Chinese rival’s launch validates the category, claimed U.S. restrictions on Chinese humanoid imports leave Realbotix as the main domestic option, and argued the new lower-priced line will help scale demand.

Scott Meyers did not give a detailed financial rundown in the prepared remarks that were included, and no revenue, EPS, or gross margin figures were stated. The closest financial commentary came from management’s discussion of accounting improvements, the exit from crypto staking, and revenue recognition timing tied to shipment rather than orders. The call also noted that roughly another $640,000 remains owed from the Tokens.com domain sale, including a payment due at the end of the month, with completion expected by the end of January 2027.

Analyst questions focused on how Realbotix can justify itself with limited revenue, how it can compete with Chinese humanoid robotics, and whether the merger timing had slipped. Management responded that the transaction timing has not changed materially, though the S-4 filing is about four weeks behind the original hope; it is now expected this month, with closing still targeted around the end of October/November. On competition and revenue, Andrew Kiguel argued that most robotics peers have little or no revenue today, that Realbotix’s moat is its realistic human-like design, modularity, wall/battery power options, OpenAI-stack compatibility, and patented vision system, and that the new DTC format will simplify ordering and scaling.